Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia
Description
Percentage of patients aged 18 years and older with a diagnosis of community-acquired bacterial pneumonia with oxygen saturation documented and reviewed
Percentage of patients aged 18 years and older with a diagnosis of community-acquired bacterial pneumonia with oxygen saturation documented and reviewed
Percentage of patients aged 18 years and older with the diagnosis of community-acquired bacterial pneumonia with oxygen saturation assessed
The percentage of patients 2 years or older with asthma who have a refill for a short-acting beta agonist in the past 12 months.
Percentage of patients with asthma who have greater than or equal to one visit to the emergency room for asthma during the measurement period.
The percentage of patients 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.
Percentage of patients, age >=18 and <= 120 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), whose primary tumor is of the colon, and had at least 12 regional lymph nodes removed and pathologically examined for resected colon cancer
The percentage of patients aged 12 years and older with coronary artery disease, or 18 years and older with cerebrovascular disease or peripheral vascular disease that have been screened for dyslipidemia with a lipid profile
The percentage of patients aged 18 and older with a diagnosis of atherosclerotic disease whose most recent LDL-C value is greater than 100 mg/dL and who are taking a lipid lowering agent
Percentage of adult patients aged 25 and older with atrial fibrillation and major stroke risk factors who are on anticoagulation therapy.
Percentage of patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS2 risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism